Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 256

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Hyperprolactinemia and Prolactinomas

Mancini, Tatiana, Casanueva, Felipe F., Giustina, Andrea·2008·Endocrinology and Metabolism Clinics of North America
DOI 10.1016/j.ecl.2007.10.013
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ecl.2007.10.013

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 184

  1. Bachelot, 2007, Reproductive role of PRL, Reproduction, 133, 361, 10.1530/REP-06-0299 · DOI · Paper page
  2. Freeman, 2000, PRL: structure, function, and regulation of secretion, Physiol Rev, 80, 1523, 10.1152/physrev.2000.80.4.1523 · DOI · Paper page
  3. Horseman, 1994, Transcriptional regulation by the helix bundle peptide hormones: growth hormone, PRL, and hematopoietic cytokines, Endocr Rev, 15, 627, 10.1210/edrv-15-5-627 · DOI · Paper page
  4. Bernichtein, 2001, S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist, Endocrinology, 142, 3950, 10.1210/endo.142.9.8369 · doi:10.1210/endo.142.9.8369
  5. Wu, 2003, Different biological effects of unmodified PRL and a molecular mimic of phosphorylated PRL involve different signaling pathways, Biochemistry, 42, 7561, 10.1021/bi034217s · doi:10.1021/bi034217s
  6. Sinha, 1995, Structural variants of PRL: occurrence and physiological significance, Endocr Rev, 16, 354, 10.1210/edrv-16-3-354 · DOI · Paper page
  7. Piwnica, 2006, A new mechanism for PRL processing into 16K PRL by secreted cathepsin D, Mol Endocrinol, 20, 3263, 10.1210/me.2006-0044 · DOI
  8. Sassin, 1972, Human prolactin: 24-hour pattern with increased release during sleep, Science, 177, 1205, 10.1126/science.177.4055.1205 · DOI · Paper page
  9. Haanwinckel, 1991, Role of central beta-adrenoceptors on stress-induced PRL release in rats, Horm Metab Res, 23, 318, 10.1055/s-2007-1003686 · DOI
  10. Wojcikiewicz, 1984, Muscarinic acetylcholine receptor activation causes inhibition of cyclic AMP accumulation, PRL and growth hormone secretion in GH3 rat anterior pituitary tumor cells, Biochim Biophys Acta, 805, 25, 10.1016/0167-4889(84)90032-6 · DOI
  11. Hill, 1991, Suckling unmasks the stimulatory effect of dopamine on PRL release: possible role for alpha-melanocyte-stimulating hormone as a mammotrope responsiveness factor, Endocrinology, 129, 843, 10.1210/endo-129-2-843 · DOI
  12. Giustina, 1994, Physiological role of galanin in the regulation of anterior pituitary function in humans, Am J Physiol, 266, E57
  13. De Marinis, 2000, Effects of galanin on growth hormone and PRL secretion in anorexia nervosa, Metabolism, 49, 155, 10.1016/S0026-0495(00)91091-6 · doi:10.1016/s0026-0495(00)91091-6
  14. Enjalbert, 1982, Reciprocal interactions of somatostatin with thyrotropin-releasing hormone and vasoactive intestinal peptide on PRL and growth hormone secretion in vitro, Endocrinology, 111, 42, 10.1210/endo-111-1-42 · DOI
  15. Racagni, 1984, Regulation of PRL secretion during suckling: involvement of the hypothalamo-pituitary GABAergic system, J Endocrinol Invest, 7, 481, 10.1007/BF03348454 · DOI
  16. Giustina, 1992, The role of glucocorticoids in the regulation of growth hormone secretion, Trends Endocrinol Metab, 3, 306, 10.1016/1043-2760(92)90142-N · DOI
  17. Sato, 1998, Corticosteroids stimulate the differentiation of growth hormone cells but suppress that of PRL cells in the fetal rat pituitary, Arch Histol Cytol, 61, 75, 10.1679/aohc.61.75 · DOI
  18. Brann, 1990, Corticosteroid regulation of gonadotropin and PRL secretion in the rat, Endocrinology, 126, 159, 10.1210/endo-126-1-159 · DOI
  19. DeMaria, 2000, Ovarian steroids influence the activity of neuroendocrine dopaminergic neurons, Brain Res, 879, 139, 10.1016/S0006-8993(00)02763-3 · DOI
  20. Snyder, 1973, Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone, J Clin Invest, 52, 2324, 10.1172/JCI107421 · DOI
  21. Bole-Feysot, 1998, PRL (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice, Endocr Rev, 19, 225, 10.1210/edrv.19.3.0334 · DOI · Paper page
  22. Bakowska, 1997, Atlas of the neurons that express mRNA for the long form of the PRL receptor in the forebrain of the female rat, J Comp Neurol, 386, 161, 10.1002/(SICI)1096-9861(19970922)386:2<161::AID-CNE1>3.0.CO;2-# · DOI
  23. Casanueva, 2006, Guidelines of the Pituitary Society for the diagnosis and management of prolactinoma, Clin Endocrinol (Oxf), 65, 265, 10.1111/j.1365-2265.2006.02562.x · DOI · Paper page
  24. Schlechte, 2003, Clinical practice. Prolactinoma, N Engl J Med, 349, 2035, 10.1056/NEJMcp025334 · DOI · Paper page
  25. Molitch, 2001, Disorders of PRL secretion, Endocrinol Metab Clin North Am, 30, 585, 10.1016/S0889-8529(05)70203-6 · DOI · Paper page
  26. Molitch, 2005, Medication-induced hyperprolactinemia, Mayo Clin Proc, 80, 1050, 10.4065/80.8.1050 · DOI · Paper page
  27. Romeo, 1996, Hyperprolactinemia and verapamil: prevalence and potential association with hypogonadism in men, Clin Endocrinol (Oxf), 45, 571, 10.1046/j.1365-2265.1996.00859.x · DOI
  28. de Burbure, 2006, Renal and neurologic effects of cadmium, lead, mercury, and arsenic in children: evidence of early effects and multiple interactions at environmental exposure levels, Environ Health Perspect, 114, 584, 10.1289/ehp.8202 · DOI · Paper page
  29. Lafuente, 2005, Toxic effects of cadmium on the regulatory mechanism of dopamine and serotonin on PRL secretion in adult male rats, Toxicol Lett, 155, 87, 10.1016/j.toxlet.2004.08.011 · doi:10.1016/j.toxlet.2004.08.011
  30. Niu, 2004, Neurobehavioral functions, serum PRL and plasma renin activity of manganese-exposed workers, Int J Immunopathol Pharmacol, 17, 17, 10.1177/03946320040170S204 · doi:10.1177/03946320040170s204
  31. Carta, 2003, Sub-clinical neurobehavioral abnormalities associated with low level of mercury exposure through fish consumption, Neurotoxicology, 24, 617, 10.1016/S0161-813X(03)00080-9 · DOI
  32. Lucchini, 2000, Assessment of neurobehavioral performance as a function of current and cumulative occupational lead exposure, Neurotoxicology, 21, 805
  33. Alessio, 2006, Prolactin changes as a consequence of chemical exposure, Environ Health Perspect, 114, A573, 10.1289/ehp.114-a573 · doi:10.1289/ehp.114-a573
  34. Waschek, 1987, Barium distinguishes separate calcium targets for synthesis and secretion of peptides in neuroendocrine cells, Biochem Biophys Res Commun, 146, 495, 10.1016/0006-291X(87)90556-0 · doi:10.1016/0006-291x(87)90556-0
  35. Schule, 2001, Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers, Pharmacopsychiatry, 34, S127, 10.1055/s-2001-15456 · DOI
  36. De Marinis, 2005, Primary empty sella, J Clin Endocrinol Metab, 90, 5471, 10.1210/jc.2005-0288 · DOI · Paper page
  37. Giustina, 2001, Clinical review 136: primary lymphoma of the pituitary: an emerging clinical entity, J Clin Endocrinol Metab, 86, 4567, 10.1210/jcem.86.10.7909 · DOI
  38. Schlechte, 1989, The natural history of untreated hyperprolactinemia: a prospective analysis, J Clin Endocrinol Metab, 68, 412, 10.1210/jcem-68-2-412 · DOI · Paper page
  39. Sluijmer, 1992, Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia, Fertil Steril, 58, 72, 10.1016/S0015-0282(16)55139-5 · DOI
  40. Ciccarelli, 2005, The epidemiology of prolactinoma, Pituitary, 8, 3, 10.1007/s11102-005-5079-0 · DOI · Paper page
  41. Hall, 1994, Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population, Ann Intern Med, 120, 817, 10.7326/0003-4819-120-10-199405150-00001 · DOI · Paper page
  42. Daly, 2006, High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium, J Clin Endocrinol Metab, 91, 4769, 10.1210/jc.2006-1668 · DOI · Paper page
  43. Vrkljan, 2006, Incidence of pituitary tumors in the human population of Croatia, Coll Antropol, 30, 157
  44. Zargar, 2004, Clinical and endocrine aspects of pituitary tumors, Saudi Med J, 25, 1428
  45. Colao, 2003, Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia, Eur J Endocrinol, 148, 325, 10.1530/eje.0.1480325 · DOI · Paper page
  46. Drange, 2000, Pituitary tumor registry: a novel clinical resource, J Clin Endocrinol Metab, 85, 168
  47. Mindermann, 1994, Age-related and gender-related occurrence of pituitary adenomas, Clin Endocrinol (Oxf), 41, 359, 10.1111/j.1365-2265.1994.tb02557.x · DOI · Paper page
  48. Fideleff, 2000, Peripubertal prolactinoma: clinical presentation and long-term outcome with different therapeutic approaches, J Pediatr Endocrinol Metab, 13, 261, 10.1515/JPEM.2000.13.3.261 · doi:10.1515/jpem.2000.13.3.261
  49. Mindermann, 1995, Pituitary adenomas in childhood and adolescence, J Pediatr Endocrinol Metab, 8, 79, 10.1515/JPEM.1995.8.2.79 · doi:10.1515/jpem.1995.8.2.79
  50. Kars, 2006, Malignant prolactinoma: case report and review of the literature, Eur J Endocrinol, 155, 523, 10.1530/eje.1.02268 · DOI
  51. Burgess, 1996, Prolactinoma in a large kindred with multiple endocrine neoplasia type 1: clinical features and inheritance pattern, J Clin Endocrinol Metab, 81, 1841
  52. Verges, 2002, Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study, J Clin Endocrinol Metab, 87, 457, 10.1210/jcem.87.2.8145 · DOI · Paper page
  53. Stratakis, 2001, Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation, J Clin Endocrinol Metab, 86, 4041, 10.1210/jcem.86.9.7903 · doi:10.1210/jcem.86.9.7903 · Paper page
  54. Berezin, 1995, Familial prolactinoma, Clin Endocrinol (Oxf), 42, 483, 10.1111/j.1365-2265.1995.tb02666.x · DOI
  55. Daly, 2006, Clinical characterization of familial isolated pituitary adenomas, J Clin Endocrinol Metab, 91, 3316, 10.1210/jc.2005-2671 · doi:10.1210/jc.2005-2671
  56. Daly, 2007, Aryl hydrocarbon receptor interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families, J Clin Endocrinol Metab, 92, 1891, 10.1210/jc.2006-2513 · DOI · Paper page
  57. Spada, 2005, Pathogenesis of prolactinoma, Pituitary, 8, 7, 10.1007/s11102-005-5080-7 · DOI
  58. Karga, 1992, Ras mutations in human pituitary tumors, J Clin Endocrinol Metab, 74, 914, 10.1210/jcem.74.4.1312542 · doi:10.1210/jcem.74.4.1312542
  59. Cristina, 2007, PTTG expression in different experimental and human prolactinoma in relation to dopaminergic control of lactotropes, Mol Cancer, 6, 1, 10.1186/1476-4598-6-4 · doi:10.1186/1476-4598-6-4
  60. Horwitz, 2003, Human pituitary tumor-transforming gene (PTTG1) motif suppresses PRL expression, Mol Endocrinol, 17, 600, 10.1210/me.2001-0006 · doi:10.1210/me.2001-0006
  61. Sarkar, 2006, Genesis of prolactinoma: studies using estrogen-treated animals, Front Horm Res, 35, 32, 10.1159/000094307 · DOI
  62. Sigala, 2004, Increased serum concentration of nerve growth factor in patients with microprolactinoma, Neuropeptides, 38, 21, 10.1016/j.npep.2003.11.002 · doi:10.1016/j.npep.2003.11.002
  63. Fiorentini, 2002, Nerve growth factor regulates dopamine D(2) receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-kappaB, Mol Endocrinol, 16, 353
  64. Ezzat, 2002, Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis, J Clin Invest, 109, 69, 10.1172/JCI14036 · DOI · Paper page
  65. Finelli, 2002, The High Mobility Group A2 gene is amplified and overexpressed in human prolactinoma, Cancer Res, 62, 2398
  66. Smith, 2007, Technology insight: measuring PRL in clinical samples, Nat Clin Pract Endocrinol Metab, 3, 279, 10.1038/ncpendmet0447 · doi:10.1038/ncpendmet0447
  67. Gibney, 2005, The impact on clinical practice of routine screening for macroprolactin, J Clin Endocrinol Metab, 90, 3927, 10.1210/jc.2004-2234 · DOI · Paper page
  68. Quinn, 2006, Determination of ultrafilterable PRL: elimination of macroprolactin interference with a monomeric PRL-selective sample pretreatment, Arch Pathol Lab Med, 130, 1807, 10.5858/2006-130-1807-DOUPEO · doi:10.5858/2006-130-1807-doupeo
  69. Hauache, 2002, Screening for macroprolactinaemia and pituitary imaging studies, Clin Endocrinol (Oxf), 57, 327, 10.1046/j.1365-2265.2002.01586.x · doi:10.1046/j.1365-2265.2002.01586.x
  70. Barkan, 1998, Giant pituitary prolactinoma with falsely low serum PRL: the pitfall of the “high-dose hook effect”: case report, Neurosurgery, 42, 913, 10.1097/00006123-199804000-00126 · DOI
  71. Naidich, 1999, Current approaches to imaging of the sellar region and pituitary, Endocrinol Metab Clin North Am, 28, 45, 10.1016/S0889-8529(05)70057-8 · DOI
  72. Giustina, 2000, Criteria for cure of acromegaly: a consensus statement, J Clin Endocrinol Metab, 85, 526
  73. Ambrosi, 1980, PRL and sexual function, JAMA, 244, 2608, 10.1001/jama.1980.03310230014010 · doi:10.1001/jama.1980.03310230014010
  74. Klibanski, 1980, Decreased bone density in hyperprolactinemic women, N Engl J Med, 303, 1511, 10.1056/NEJM198012253032605 · DOI · Paper page
  75. Schlechte, 1987, Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea, J Clin Endocrinol Metab, 64, 1021, 10.1210/jcem-64-5-1021 · DOI
  76. Adler, 1998, Relative effects of PRL excess and estrogen deficiency on bone in rats, Metabolism, 47, 425, 10.1016/S0026-0495(98)90054-3 · DOI
  77. Kok, 2006, Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women, Am J Physiol Endocrinol Metab, 291, 1038, 10.1152/ajpendo.00567.2005 · DOI
  78. Alvarez-Nemegyei, 1998, Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study, Lupus, 7, 414, 10.1191/096120398678920334 · DOI
  79. March, 1981, Longitudinal evaluation of patients with untreated PRL-secreting pituitary adenomas, Am J Obstet Gynecol, 139, 835, 10.1016/0002-9378(81)90553-6 · DOI
  80. Weiss, 1983, Natural history of microprolactinoma: six-year follow-up, Neurosurgery, 12, 180, 10.1227/00006123-198302000-00008 · DOI
  81. Gillam, 2006, Advances in the treatment of prolactinoma, Endocr Rev, 27, 485, 10.1210/er.2005-9998 · DOI · Paper page
  82. Molitch, 1999, Medical treatment of prolactinoma, Endocrinol Metab Clin North Am, 28, 143, 10.1016/S0889-8529(05)70061-X · DOI · Paper page
  83. Corenblum, 1993, The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia, Fertil Steril, 59, 671, 10.1016/S0015-0282(16)55819-1 · DOI
  84. Fahy, 1992, The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea, Gynecol Endocrinol, 6, 183, 10.3109/09513599209015553 · DOI
  85. Testa, 1998, Two-year treatment with oral contraceptives in hyperprolactinemic patients, Contraception, 58, 69, 10.1016/S0010-7824(98)00069-9 · DOI
  86. Garcia, 1995, Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy, J Endocrinol Invest, 18, 450, 10.1007/BF03349744 · DOI
  87. Kovacs, 1994, PRL-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study, Arch Pathol Lab Med, 118, 562
  88. Orrego, 2000, Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine, Pituitary, 3, 189, 10.1023/A:1011412028660 · doi:10.1023/a:1011412028660
  89. Colao, 2003, Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia, N Engl J Med, 349, 2023, 10.1056/NEJMoa022657 · DOI · Paper page
  90. Johnston, 1984, Effect of dopamine agonist withdrawal after long-term therapy in prolactinoma. Studies with high-definition computerised tomography, Lancet, 2, 187, 10.1016/S0140-6736(84)90480-X · DOI
  91. Passos, 2002, Long-term follow-up of prolactinoma: normoPRLemia after bromocriptine withdrawal, J Clin Endocrinol Metab, 87, 3578, 10.1210/jcem.87.8.8722 · DOI
  92. Biswas, 2005, Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinoma, Clin Endocrinol (Oxf), 63, 26, 10.1111/j.1365-2265.2005.02293.x · DOI
  93. Wass, 2006, When to discontinue treatment of prolactinoma?, Nat Clin Pract Endocrinol Metab, 2, 298, 10.1038/ncpendmet0162 · doi:10.1038/ncpendmet0162
  94. Bronstein, 2006, Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy, Nat Clin Pract Endocrinol Metab, 2, 130, 10.1038/ncpendmet0135 · doi:10.1038/ncpendmet0135
  95. Crosignani, 1992, Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women, Eur J Obstet Gynecol Reprod Biol, 44, 175, 10.1016/0028-2243(92)90094-F · DOI
  96. Jeffcoate, 1996, Long-term follow-up of patients with hyperprolactinemia, Clin Endocrinol (Oxf), 45, 299, 10.1046/j.1365-2265.1996.00824.x · DOI
  97. Karunakaran, 2001, The effect of the menopause on PRL levels in patients with hyperprolactinemia, Clin Endocrinol (Oxf), 54, 295, 10.1046/j.1365-2265.2001.01190.x · DOI
  98. Crosignani, 1978, Antiserotonin treatment of hyperprolactinemic amenorrhea: long-term follow-up with metergoline, methysergide, and cyproheptadine, Am J Obstet Gynecol, 132, 307, 10.1016/0002-9378(78)90898-0 · doi:10.1016/0002-9378(78)90898-0
  99. Bohnet, 1986, Treatment of hyperprolactinemic amenorrhea with Metergoline, Obstet Gynecol, 67, 249, 10.1097/00006250-198602000-00016 · doi:10.1097/00006250-198602000-00016
  100. Wood, 1991, Dopamine, the dopamine D2 receptor and pituitary tumors, Clin Endocrinol (Oxf), 35, 455, 10.1111/j.1365-2265.1991.tb00928.x · DOI
  101. Gen, 1984, Necrotic changes in prolactinoma after long term administration of bromocriptine, J Clin Endocrinol Metab, 59, 463, 10.1210/jcem-59-3-463 · DOI
  102. Molitch, 1985, Bromocriptine as primary therapy for PRL-secreting macroadenomas: results of a prospective multicenter study, Clin Endocrinol Metab, 60, 698, 10.1210/jcem-60-4-698 · DOI · Paper page
  103. Weiss, 1983, Bromocriptine treatment of PRL-secreting tumors: surgical implications, Neurosurgery, 12, 640, 10.1227/00006123-198306000-00008 · doi:10.1227/00006123-198306000-00008
  104. Di Somma, 1998, Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males, J Clin Endocrinol Metab, 83, 807, 10.1210/jcem.83.3.4674 · doi:10.1210/jcem.83.3.4674 · Paper page
  105. Klibanski, 1986, Increase in bone mass after treatment of hyperprolactinemic amenorrhea, N Engl J Med, 315, 542, 10.1056/NEJM198608283150903 · DOI · Paper page
  106. De Rosa, 1998, Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine, Eur J Endocrinol, 138, 286, 10.1530/eje.0.1380286 · DOI
  107. Kissner, 1980, Side effects of bromocriptine, N Engl J Med, 302, 749, 10.1056/NEJM198003273021313 · doi:10.1056/nejm198003273021313
  108. Webster, 1996, A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation, Drug Saf, 14, 228, 10.2165/00002018-199614040-00003 · DOI · Paper page
  109. Pearson, 1981, Mental disorders from low-dose bromocriptine, N Engl J Med, 305, 173, 10.1056/NEJM198107163050321 · doi:10.1056/nejm198107163050321
  110. Turner, 1984, Psychotic reactions during treatment of pituitary tumors with dopamine agonists, Br Med J (Clin Res Ed), 289, 1101, 10.1136/bmj.289.6452.1101 · DOI
  111. Baskin, 1982, CSF rhinorrhea after bromocriptine for prolactinoma, N Engl J Med, 306, 178, 10.1056/NEJM198201213060322 · doi:10.1056/nejm198201213060322
  112. Andreotti, 1995, Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a PRL-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers, J Clin Endocrinol Metab, 80, 841
  113. Ferrari, 1986, Long-lasting PRL-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients, J Clin Endocrinol Metab, 63, 941, 10.1210/jcem-63-4-941 · DOI
  114. Ferrari, 1997, Treatment of macroprolactinoma with cabergoline: a study of 85 patients, Clin Endocrinol (Oxf), 46, 409, 10.1046/j.1365-2265.1997.1300952.x · DOI
  115. Webster, 1994, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group, N Engl J Med, 331, 904, 10.1056/NEJM199410063311403 · DOI · Paper page
  116. Verhelst, 1999, Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients, J Clin Endocrinol Metab, 84, 2518, 10.1210/jcem.84.7.5810 · DOI · Paper page
  117. Ciccarelli, 1989, Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients, J Clin Endocrinol Metab, 69, 725, 10.1210/jcem-69-4-725 · DOI
  118. Colao, 2000, Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients, J Clin Endocrinol Metab, 85, 2247
  119. Colao, 1997, Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage, J Clin Endocrinol Metab, 82, 3574, 10.1210/jcem.82.11.4368 · DOI · Paper page
  120. Shimon, 2007, Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men, Eur J Endocrinol, 156, 225, 10.1530/EJE-06-0646 · DOI
  121. Rains, 1995, Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinemia and inhibition of lactation, Drugs, 49, 255, 10.2165/00003495-199549020-00009 · DOI
  122. Melis, 1989, Reduction in the size of PRL-producing pituitary tumor after cabergoline administration, Fertil Steril, 52, 412, 10.1016/S0015-0282(16)60909-3 · DOI
  123. Zanettini, 2007, Valvular heart disease and the use of dopamine agonists for Parkinson's disease, N Engl J Med, 356, 39, 10.1056/NEJMoa054830 · DOI · Paper page
  124. Schade, 2007, Dopamine agonists and the risk of cardiac-valve regurgitation, N Engl J Med, 356, 29, 10.1056/NEJMoa062222 · DOI · Paper page
  125. Horvath, 2004, Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists, Mov Disord, 19, 656, 10.1002/mds.20201 · DOI · Paper page
  126. Pinero, 2005, Cabergoline-related severe restrictive mitral regurgitation, N Engl J Med, 353, 1976, 10.1056/NEJM200511033531822 · DOI
  127. Colao, 1997, Prolactinoma resistant to standard dopamine agonists respond to chronic cabergoline treatment, J Clin Endocrinol Metab, 82, 876, 10.1210/jcem.82.3.3822 · doi:10.1210/jcem.82.3.3822 · Paper page
  128. Ferrari, 1989, Cabergoline: long-acting oral treatment of hyperprolactinemic disorders, J Clin Endocrinol Metab, 68, 1201, 10.1210/jcem-68-6-1201 · DOI
  129. Ferrari, 1992, Cabergoline in the long-term therapy of hyperprolactinemic disorders, Acta Endocrinol (Copenh), 126, 489
  130. Lamberts, 1991, A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia, J Clin Endocrinol Metab, 72, 635, 10.1210/jcem-72-3-635 · DOI
  131. Franks, 1981, Treatment of hyperprolactinaemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment, Lancet, 2, 659, 10.1016/S0140-6736(81)90997-1 · doi:10.1016/s0140-6736(81)90997-1
  132. Kleinberg, 1983, Pergolide for the treatment of pituitary tumors secreting PRL or growth hormone, N Engl J Med, 309, 704, 10.1056/NEJM198309223091205 · DOI
  133. Orrego, 2000, Pergolide as primary therapy for macroprolactinoma, Pituitary, 3, 251, 10.1023/A:1012836331506 · DOI
  134. Vance, 1989, CV 205–502 treatment of hyperprolactinemia, J Clin Endocrinol Metab, 68, 336, 10.1210/jcem-68-2-336 · DOI
  135. Vance, 1990, Treatment of PRL-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205–502, Ann Intern Med, 112, 668, 10.7326/0003-4819-112-9-668 · DOI
  136. Di Sarno, 2000, The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinoma, Clin Endocrinol (Oxf), 53, 53, 10.1046/j.1365-2265.2000.01016.x · DOI
  137. De Luis, 2000, A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients, J Endocrinol Invest, 23, 428, 10.1007/BF03343751 · doi:10.1007/bf03343751
  138. Giusti, 1994, A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients, J Endocrinol Invest, 17, 51, 10.1007/BF03344963 · doi:10.1007/bf03344963
  139. Gola, 2006, Resistance to somatostatin analogs in acromegaly: an evolving concept?, J Endocrinol Invest, 29, 86, 10.1007/BF03349183 · DOI
  140. Olafsdottir, 2006, Management of resistant prolactinoma, Nat Clin Pract Endocrinol Metab, 2, 552, 10.1038/ncpendmet0290 · DOI
  141. Molitch, 2005, Pharmacologic resistance in prolactinoma patients, Pituitary, 8, 43, 10.1007/s11102-005-5085-2 · DOI · Paper page
  142. Pellegrini, 1989, Resistance to bromocriptine in prolactinoma, J Clin Endocrinol Metab, 69, 500, 10.1210/jcem-69-3-500 · DOI · Paper page
  143. Caccavelli, 1994, Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinoma, Neuroendocrinology, 60, 314, 10.1159/000126764 · DOI · Paper page
  144. Tulipano, 2007, Novel insights in somatostatin receptor physiology, Eur J Endocrinol, 156, S3, 10.1530/eje.1.02354 · DOI
  145. Jaquet, 1999, Quantitative and functional expression of somatostatin receptor subtypes in human prolactinoma, J Clin Endocrinol Metab, 84, 3268
  146. Tulipano, 2001, Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro, Neuroendocrinology, 73, 344, 10.1159/000054651 · DOI
  147. Shimon, 1997, Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and PRL in human pituitary adenomas. Novel potential therapy for functional pituitary tumors, J Clin Invest, 100, 2386, 10.1172/JCI119779 · DOI · Paper page
  148. Hofland, 2004, The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and PRL-secreting pituitary adenomas in vitro, J Clin Endocrinol Metab, 89, 1577, 10.1210/jc.2003-031344 · DOI · Paper page
  149. Jaquet, 2005, Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and PRL secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy, Eur J Endocrinol, 153, 135, 10.1530/eje.1.01950 · doi:10.1530/eje.1.01950
  150. Goffin, 2005, Development and potential clinical uses of human PRL receptor antagonists, Endocr Rev, 26, 400, 10.1210/er.2004-0016 · DOI · Paper page
  151. Losa, 2002, Surgical treatment of PRL-secreting pituitary adenomas: early results and long-term outcome, J Clin Endocrinol Metab, 87, 3180, 10.1210/jcem.87.7.8645 · doi:10.1210/jcem.87.7.8645 · Paper page
  152. Cappabianca, 2004, Endoscopic endonasal transsphenoidal surgery, Neurosurgery, 55, 933, 10.1227/01.NEU.0000137330.02549.0D · doi:10.1227/01.neu.0000137330.02549.0d
  153. Thomson, 1994, Ten year follow up of microprolactinoma treated by transsphenoidal surgery, BMJ, 309, 1409, 10.1136/bmj.309.6966.1409 · doi:10.1136/bmj.309.6966.1409
  154. Amar, 2002, Predictive value of serum PRL levels measured immediately after transsphenoidal surgery, J Neurosurg, 97, 307, 10.3171/jns.2002.97.2.0307 · doi:10.3171/jns.2002.97.2.0307
  155. Nelson, 1984, Residual anterior pituitary function following transsphenoidal resection of pituitary macroadenomas, J Neurosurg, 61, 577, 10.3171/jns.1984.61.3.0577 · DOI
  156. Landolt, 1982, Bromocriptine: does it jeopardise the result of later surgery for prolactinoma?, Lancet, 2, 657, 10.1016/S0140-6736(82)92756-8 · doi:10.1016/s0140-6736(82)92756-8
  157. Bevan, 1987, Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumor, including pre-operative bromocriptine therapy, Clin Endocrinol (Oxf), 26, 541, 10.1111/j.1365-2265.1987.tb00809.x · DOI
  158. Fahlbusch, 1984, Influence of preoperative bromocriptine therapy on success of surgery for microprolactinoma, Lancet, 2, 520, 10.1016/S0140-6736(84)92596-0 · doi:10.1016/s0140-6736(84)92596-0
  159. Sudhakar, 2004, Complications after trans-sphenoidal surgery: our experience and a review of the literature, Br J Neurosurg, 18, 507, 10.1080/02688690400012459a · DOI
  160. Johnston, 1986, The long-term effects of megavoltage radiotherapy as sole or combined therapy for large prolactinoma: studies with high definition computerized tomography, Clin Endocrinol (Oxf), 24, 675, 10.1111/j.1365-2265.1986.tb01664.x · DOI
  161. Tsagarakis, 1991, Megavoltage pituitary irradiation in the management of prolactinoma: long-term follow-up, Clin Endocrinol (Oxf), 34, 399, 10.1111/j.1365-2265.1991.tb00312.x · DOI
  162. Kuo, 2004, Gamma knife radiosurgery for benign cavernous sinus tumors: quantitative analysis of treatment outcomes, Neurosurgery, 54, 1385, 10.1227/01.NEU.0000124750.13721.94 · doi:10.1227/01.neu.0000124750.13721.94
  163. Landolt, 2000, Gamma knife radiosurgery for prolactinoma, J Neurosurg, 93, 14, 10.3171/jns.2000.93.supplement_3.0014 · doi:10.3171/jns.2000.93.supplement_3.0014
  164. Popadic, 1999, Malignant prolactinoma: case report and review of the literature, Surg Neurol, 51, 47, 10.1016/S0090-3019(97)00458-8 · DOI
  165. Kaltsas, 2005, Clinical review: diagnosis and management of pituitary carcinomas, J Clin Endocrinol Metab, 90, 3089, 10.1210/jc.2004-2231 · DOI · Paper page
  166. Gurlek, 2007, What are the markers of aggressiveness in prolactinoma? Changes in cell biology, extracellular matrix components, angiogenesis and genetics, Eur J Endocrinol, 156, 143, 10.1530/eje.1.02339 · DOI
  167. Elster, 1991, Size and shape of the pituitary gland during pregnancy and post partum: measurement with MR imaging, Radiology, 181, 531, 10.1148/radiology.181.2.1924800 · DOI · Paper page
  168. Molitch, 1985, Pregnancy and the hyperprolactinemic woman, N Engl J Med, 312, 1364, 10.1056/NEJM198505233122106 · DOI
  169. Rjosk, 1982, Influence of pregnancies on prolactinoma, Acta Endocrinol (Copenh), 100, 337
  170. Ahmed, 1992, Macroprolactinoma with suprasellar extension: effect of bromocriptine withdrawal during one or more pregnancies, Fertil Steril, 58, 492, 10.1016/S0015-0282(16)55250-9 · doi:10.1016/s0015-0282(16)55250-9
  171. Bronstein, 2005, Prolactinoma and pregnancy, Pituitary, 8, 31, 10.1007/s11102-005-5083-4 · DOI
  172. Gemzell, 1979, Outcome of pregnancy in women with pituitary adenoma, Fertil Steril, 31, 363, 10.1016/S0015-0282(16)43929-4 · DOI · Paper page
  173. Rossi, 1995, Outcome of pregnancies in women with treated or untreated hyperprolactinemia, Eur J Obstet Gynecol Reprod Biol, 63, 143, 10.1016/0301-2115(95)02257-0 · DOI
  174. Konopka, 1983, Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinoma, Am J Obstet Gynecol, 146, 935, 10.1016/0002-9378(83)90968-7 · DOI
  175. Krupp, 1987, Bromocriptine in pregnancy: safety aspects, Klin Wochenschr, 65, 823, 10.1007/BF01727477 · DOI
  176. Raymond, 1985, Follow-up of children born of bromocriptine-treated mothers, Horm Res, 22, 239, 10.1159/000180100 · DOI
  177. De Mari, 2002, Antiparkinsonian treatment in pregnancy, Mov Disord, 17, 428, 10.1002/mds.10040 · DOI
  178. Morange, 1996, Prolactinoma resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy, Eur J Endocrinol, 135, 413, 10.1530/eje.0.1350413 · DOI
  179. Robert, 1996, Pregnancy outcome after treatment with the ergot derivative, cabergoline, Reprod Toxicol, 10, 333, 10.1016/0890-6238(96)00063-9 · DOI · Paper page
  180. Ricci, 2002, Pregnancy outcome after cabergoline treatment in early weeks of gestation, Reprod Toxicol, 16, 791, 10.1016/S0890-6238(02)00055-2 · DOI
  181. Molitch, 2006, Pituitary disorders during pregnancy, Endocrinol Metab Clin North Am, 35, 99, 10.1016/j.ecl.2005.09.011 · DOI
  182. Divers, 1983, PRL-producing microadenomas in pregnancy, Obstet Gynecol, 62, 425
  183. Kupersmith, 1994, Visual loss in pregnant women with pituitary adenomas, Ann Intern Med, 121, 473, 10.7326/0003-4819-121-7-199410010-00001 · DOI
  184. Belchetz, 1986, Failure of prophylactic surgery to avert massive pituitary expansion in pregnancy, Clin Endocrinol (Oxf), 25, 325, 10.1111/j.1365-2265.1986.tb01698.x · DOI

Cited by

See all 256

Metadata

Authors
Mancini, T., Casanueva, F. F., & Giustina, A.
Venue
Endocrinology and Metabolism Clinics of North America
Publisher
Elsevier BV
Published
2008-03
Volume
37
Issue
1
Pages
67-99
ISSN
0889-8529 (ISSN-L)
DOI
10.1016/j.ecl.2007.10.013
OpenAlex
W2073194318
Cited by
256
References
3
FWCI
11.11
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hyperprolactinemia and Prolactinomas. https://app.cochat.ai/papers/10.1016/j.ecl.2007.10.013
The paper
Mancini, T., Casanueva, F. F., & Giustina, A. (2008). Hyperprolactinemia and Prolactinomas. Endocrinology and Metabolism Clinics of North America. https://doi.org/10.1016/j.ecl.2007.10.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.